Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pro-ocular 1% in Scleral Lens Wearers with Ocular GvHD
NCT04769648Phase 3Unknown
- Start
- Apr 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Crinone in ocular graft-versus-host disease (oGVHD) (2 arms). Primary endpoint: Change in Modified Symptom Assessment in Dry Eye Questionnaire, Global Score for nighttime without scleral lenses at 12 weeks. Status: unknown.
02
Drugs
Crinone
03
Conditions
ocular graft-versus-host disease (oGVHD)
Beyond the preview
Go deeper on NCT04769648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04769648.